Afficher la notice abrégée

dc.rights.licenseopenen_US
hal.structure.identifierLaboratoire Angiogenèse et Micro-environnement des Cancers [LAMC]
dc.contributor.authorGUYON, Joris
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorGOUVERNEUR, Amandine
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorMAUMUS-ROBERT, Sandy
dc.contributor.authorBERARD, Xavier
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorPARIENTE, Antoine
IDREF: 13395711X
hal.structure.identifierLaboratoire Angiogenèse et Micro-environnement des Cancers [LAMC]
dc.contributor.authorBIKFALVI, Andreas
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorNOIZE, Pernelle
dc.date.accessioned2021-05-11T12:22:38Z
dc.date.available2021-05-11T12:22:38Z
dc.date.issued2021-03-18
dc.identifier.issn2374-2445 (Electronic) 2374-2437 (Linking)en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/72141
dc.description.abstractEnAnticancer drugs targeting angiogenesis act either directly on vascular endothelial growth factor (VEGF) receptors (VEGF inhibitors) or VEGF-mediated intracellular processes (tyrosine kinase inhibitors) or indirectly through downstream VEGF signaling within broader processes (mammalian target of rapamycin inhibitors and multiprotein kinase inhibitors). Although VEGF blockade may be implicated in arterial wall injuries, the literature on the association between antiangiogenic drugs and artery dissections or aneurysms is scant, comprising only a few case reports and 1 pharmacovigilance study conducted in Japan.1 The present study evaluated the association between all antiangiogenic drugs and dissections or aneurysms occurring in all arteries.
dc.language.isoENen_US
dc.title.enAssociation Between Antiangiogenic Drugs Used for Cancer Treatment and Artery Dissections or Aneurysms
dc.typeArticle de revueen_US
dc.identifier.doi10.1001/jamaoncol.2021.0210en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed33734295en_US
bordeaux.journalJAMA oncologyen_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - U1219en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.teamPharmacoEpi-Drugsen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.identifierhal-03224166
hal.version1
hal.date.transferred2021-05-11T12:22:43Z
hal.exporttrue
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=JAMA%20oncology&rft.date=2021-03-18&rft.eissn=2374-2445%20(Electronic)%202374-2437%20(Linking)&rft.issn=2374-2445%20(Electronic)%202374-2437%20(Linking)&rft.au=GUYON,%20Joris&GOUVERNEUR,%20Amandine&MAUMUS-ROBERT,%20Sandy&BERARD,%20Xavier&PARIENTE,%20Antoine&rft.genre=article


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée